Biomarker testing can help support a diagnosis of early-stage Alzheimer's disease (AD).1,2
In what percentage of patients with MCI is AD the underlying cause?
AD is the underlying cause of MCI* in 34%-75% of patients.
*In the Aging, Demographics and Memory Study (ADAMS), patients were classified as having cognitive impairment without dementia.
What biomarker test can be utilized at the MCI stage specifically to verify amyloid beta accumulation?
The underlying pathology of AD may be determined via amyloid beta cerebrospinal fluid test.
What non-pharmaceutical intervention has been shown to slow or reverse cognitive decline?
Managing vascular risk, changing diet, increasing exercise, and doing cognitive exercises have all been shown to improve cognition.
Do you know someone who knows MCI? Share this quiz.
MCI=mild cognitive impairment.
MMSE is a registered trademark of Psychological Assessment Resources.
Receive updated news and perspectives about Alzheimer’s disease
The progression of Alzheimer’s